A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine

Aruna Rao, Bizu Gelaye, Tobias Kurth, Paul D. Dash, Haley Nitchie, B. Lee Peterlin

Research output: Contribution to journalArticle

Abstract

Objective To compare the efficacy of ketorolac nasal spray (NS) vs placebo and sumatriptan NS for the acute treatment of migraine. Methods This was a randomized, double-blind, placebo and active-comparator, crossover study. Adult migraineurs were randomized to ketorolac NS 31.5 mg, sumatriptan NS 20 mg, or placebo to treat three moderate to severe migraine attacks and switched treatments with each attack. Patients seeking headache care at a headache center or in response to community advertisement were recruited. Adult participants with episodic migraine who experienced ≥2 migraine attacks per month were eligible for the Ketorolac vs Sumatriptan vs Placebo Nasal Spray migraine study. Participants were randomized to treatment arms by a research pharmacist, in a 1:1:1 ratio using computer-generated lists. The primary outcome was 2-hour pain relief. Secondary outcomes included 2-hour pain freedom and absence of migraine associated symptoms, and 24-hour sustained pain relief and pain freedom. Results Of the 72 randomized participants, 54 (75%) treated at least one attack and 49 (68%) completed all three treatments, for a total of 152 treated migraine attacks. Both ketorolac NS (72.5%, P

Original languageEnglish (US)
Pages (from-to)331-340
Number of pages10
JournalHeadache
Volume56
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Ketorolac
Nasal Sprays
Migraine Disorders
Placebos
Sumatriptan
Pain
Headache
Therapeutics
Pharmacists
Cross-Over Studies
Research

Keywords

  • intranasal
  • ketorolac
  • migraine
  • moderate to severe pain
  • nasal spray
  • nonsteroidal anti-inflammatory
  • sumatriptan
  • treatment
  • triptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rao, A., Gelaye, B., Kurth, T., Dash, P. D., Nitchie, H., & Peterlin, B. L. (2016). A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine. Headache, 56(2), 331-340. https://doi.org/10.1111/head.12767

A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine. / Rao, Aruna; Gelaye, Bizu; Kurth, Tobias; Dash, Paul D.; Nitchie, Haley; Peterlin, B. Lee.

In: Headache, Vol. 56, No. 2, 01.02.2016, p. 331-340.

Research output: Contribution to journalArticle

Rao, A, Gelaye, B, Kurth, T, Dash, PD, Nitchie, H & Peterlin, BL 2016, 'A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine', Headache, vol. 56, no. 2, pp. 331-340. https://doi.org/10.1111/head.12767
Rao, Aruna ; Gelaye, Bizu ; Kurth, Tobias ; Dash, Paul D. ; Nitchie, Haley ; Peterlin, B. Lee. / A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine. In: Headache. 2016 ; Vol. 56, No. 2. pp. 331-340.
@article{784c258ea6bf48be8294444090297732,
title = "A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine",
abstract = "Objective To compare the efficacy of ketorolac nasal spray (NS) vs placebo and sumatriptan NS for the acute treatment of migraine. Methods This was a randomized, double-blind, placebo and active-comparator, crossover study. Adult migraineurs were randomized to ketorolac NS 31.5 mg, sumatriptan NS 20 mg, or placebo to treat three moderate to severe migraine attacks and switched treatments with each attack. Patients seeking headache care at a headache center or in response to community advertisement were recruited. Adult participants with episodic migraine who experienced ≥2 migraine attacks per month were eligible for the Ketorolac vs Sumatriptan vs Placebo Nasal Spray migraine study. Participants were randomized to treatment arms by a research pharmacist, in a 1:1:1 ratio using computer-generated lists. The primary outcome was 2-hour pain relief. Secondary outcomes included 2-hour pain freedom and absence of migraine associated symptoms, and 24-hour sustained pain relief and pain freedom. Results Of the 72 randomized participants, 54 (75{\%}) treated at least one attack and 49 (68{\%}) completed all three treatments, for a total of 152 treated migraine attacks. Both ketorolac NS (72.5{\%}, P",
keywords = "intranasal, ketorolac, migraine, moderate to severe pain, nasal spray, nonsteroidal anti-inflammatory, sumatriptan, treatment, triptan",
author = "Aruna Rao and Bizu Gelaye and Tobias Kurth and Dash, {Paul D.} and Haley Nitchie and Peterlin, {B. Lee}",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/head.12767",
language = "English (US)",
volume = "56",
pages = "331--340",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine

AU - Rao, Aruna

AU - Gelaye, Bizu

AU - Kurth, Tobias

AU - Dash, Paul D.

AU - Nitchie, Haley

AU - Peterlin, B. Lee

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective To compare the efficacy of ketorolac nasal spray (NS) vs placebo and sumatriptan NS for the acute treatment of migraine. Methods This was a randomized, double-blind, placebo and active-comparator, crossover study. Adult migraineurs were randomized to ketorolac NS 31.5 mg, sumatriptan NS 20 mg, or placebo to treat three moderate to severe migraine attacks and switched treatments with each attack. Patients seeking headache care at a headache center or in response to community advertisement were recruited. Adult participants with episodic migraine who experienced ≥2 migraine attacks per month were eligible for the Ketorolac vs Sumatriptan vs Placebo Nasal Spray migraine study. Participants were randomized to treatment arms by a research pharmacist, in a 1:1:1 ratio using computer-generated lists. The primary outcome was 2-hour pain relief. Secondary outcomes included 2-hour pain freedom and absence of migraine associated symptoms, and 24-hour sustained pain relief and pain freedom. Results Of the 72 randomized participants, 54 (75%) treated at least one attack and 49 (68%) completed all three treatments, for a total of 152 treated migraine attacks. Both ketorolac NS (72.5%, P

AB - Objective To compare the efficacy of ketorolac nasal spray (NS) vs placebo and sumatriptan NS for the acute treatment of migraine. Methods This was a randomized, double-blind, placebo and active-comparator, crossover study. Adult migraineurs were randomized to ketorolac NS 31.5 mg, sumatriptan NS 20 mg, or placebo to treat three moderate to severe migraine attacks and switched treatments with each attack. Patients seeking headache care at a headache center or in response to community advertisement were recruited. Adult participants with episodic migraine who experienced ≥2 migraine attacks per month were eligible for the Ketorolac vs Sumatriptan vs Placebo Nasal Spray migraine study. Participants were randomized to treatment arms by a research pharmacist, in a 1:1:1 ratio using computer-generated lists. The primary outcome was 2-hour pain relief. Secondary outcomes included 2-hour pain freedom and absence of migraine associated symptoms, and 24-hour sustained pain relief and pain freedom. Results Of the 72 randomized participants, 54 (75%) treated at least one attack and 49 (68%) completed all three treatments, for a total of 152 treated migraine attacks. Both ketorolac NS (72.5%, P

KW - intranasal

KW - ketorolac

KW - migraine

KW - moderate to severe pain

KW - nasal spray

KW - nonsteroidal anti-inflammatory

KW - sumatriptan

KW - treatment

KW - triptan

UR - http://www.scopus.com/inward/record.url?scp=84958963654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958963654&partnerID=8YFLogxK

U2 - 10.1111/head.12767

DO - 10.1111/head.12767

M3 - Article

C2 - 26840902

AN - SCOPUS:84958963654

VL - 56

SP - 331

EP - 340

JO - Headache

JF - Headache

SN - 0017-8748

IS - 2

ER -